VALD

About

VALD provides an integrated SaaS platform with a hardware ecosystem for musculoskeletal assessment and rehabilitation, aggregating device data (force plates, strength/ROM tools, movement analysis, TeleHab) for clinicians and teams.

Mission

VALD provides an integrated suite of musculoskeletal assessment and rehabilitation technologies centered on a software hub populated by data from devices such as force plates, strength-testing systems, handheld strength and ROM tools, movement analysis, timing gates, jump mats and a TeleHab exercise-prescription app. The company plans to use a growth equity investment to expand geographically, launch new product offerings and capabilities, and accelerate AI-driven applications built on its proprietary dataset of tens of millions of MSK health records. VALD reports rapid market growth since its 2015 founding, with revenue more than tripling since 2021, staff across over 30 countries, and a dataset that roughly doubles each year. Its customers include over 75% of major league sports franchises, over 90% of Power 5 NCAA colleges, 20 Premier League teams, the U.S. Olympic Team, branches of the U.S. military, and thousands of health systems and clinics. The product suite targets clinicians across small practices to large health systems, professional sports teams and tactical operators to improve diagnostics, capture real-time data, and drive better outcomes. VALD positions itself as a first mover in an underserviced MSK market by combining hardware, software, and a growing dataset to enable lab-grade assessment outside traditional labs. VALD builds human-measurement technologies delivered via a software-as-a-service platform used by professional sports teams and healthcare practitioners to monitor performance, injury and recovery. Its platform is employed by customers including English Premier League clubs, NBA and NFL teams, the Mayo Clinic and Kantonsspital Winterthur. The company says its tools remove subjectivity by capturing objective, visualisable data to support treatment plans and clinical research. VALD has expanded through in-house product development and acquisitions to serve physiotherapists and other allied health professionals. It reported that more than 50% of company revenues are generated in North America and has been growing headcount, adding around 100 staff in 2022 and maintaining a Queensland-based team of over 120. VALD plans to use new capital to expand its team further and to complete three acquisitions to broaden its product base and accelerate international, particularly North American, growth.

Quick Facts